BioCatalystWatch
TBPHWorkspace / TBPH / OverviewCompany library
Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc.

Theravance Biopharma, Inc. (TBPH)

Website

Featured programme · Velusetrag

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

Approved / commercial

muscarinic receptor × β2-adrenergic receptor

Approved

PreINDP1P2P3FilingApproved

muscarinic receptor × β2-adrenergic receptor

Approved

PreINDP1P2P3FilingApproved

Muscarinic receptors

Approved

PreINDP1P2P3FilingApproved

History / paused

JAK3

PreINDP1P2P3FilingApproved

HCV NS5A

PreINDP1P2P3FilingApproved

JAK1 × JAK2 × JAK3 × TYK2

PreINDP1P2P3FilingApproved

JAK1 × JAK2 × JAK3 × TYK2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing


PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing


PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

TBPH PR & News

PR & News

TBPH SEC archive